Skip to content

TTRX TTRX Operating Lease Liabilities (Total)

Operating Lease Liabilities (Total) at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$266.8M+13.8%
Journey Medical Corporation logo
Journey Medical CorporationDERM
$94K-49.7%
PTH
Pelthos Therapeutics Inc.PTHS
$3.29M
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$77.62M-6.3%
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
$16.08M+4,087%

Other financials

Income statement

See full
Operating income-$1.2M-224%
Net income-$971.0K-196%
EPS (diluted)-$0.03-200%

Balance sheet

See full
Cash & equivalents$11.2M+613%
Total debt$6.0M
Total equity$6.1M+647%
Total assets$18.6M

Cash flow

See full
Operating cash flow-$1.6M-448%

Valuation

See full
Market cap$217.45M-17.7%
Enterprise value$212.24M

Returns & leverage

See full
Return on equity-118.8%
Debt / equity
Current ratio2.2×

Where this comes from

Reported directly by TTRX in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.

The official record: TTRX’s 10-K, filed March 31, 2026, on SEC EDGAR. View the filing →

Ask your AI about TTRX's operating lease liabilities (total).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TTRX's operating lease liabilities (total)?
TTRX (TTRX) reported operating lease liabilities (total) of $80.38K in Q4 2025.
What does operating lease liabilities (total) mean?
This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.